A CoolSculpting lawsuit is a product liability claim against Zeltiq Aesthetics and its corporate parents, Allergan Aesthetics and AbbVie, alleging that the fat-freezing device caused a disfiguring side effect called paradoxical adipose hyperplasia (PAH) and that the manufacturer failed to adequately warn patients about the risk. Cases have been filed individually rather than as a class action or multidistrict litigation, and results so far have gone both ways: supermodel Linda Evangelista settled a $50 million claim in 2022, but a federal appeals court ruled in 2023 that the manufacturer’s warnings were legally adequate.
The Injury Behind the Cases
CoolSculpting is a cryolipolysis device that uses controlled cooling to destroy fat cells. Paradoxical adipose hyperplasia is the opposite of the intended result. Instead of shrinking, the treated fat cells grow larger and harden into a firm, well-defined mass that often takes the shape of the applicator head; clinicians have described the bulges as resembling a “stick of butter.” PAH typically appears weeks to months after treatment and does not resolve on its own. Correcting it usually requires liposuction or surgical excision, sometimes with specialized ultrasound-assisted techniques, and patients are advised to wait at least six months to let inflammation subside before surgery. Additional CoolSculpting sessions are not recommended, as they can make PAH worse.1National Library of Medicine. Paradoxical Adipose Hyperplasia
PAH is the injury that virtually every CoolSculpting lawsuit turns on. Damages sought include the cost of corrective surgery, medical bills, lost income, pain and suffering, and emotional distress.
What Plaintiffs Are Alleging
Complaints generally rest on three theories: failure to warn, product liability including defective design, and negligence. Plaintiffs allege Zeltiq knew about PAH as early as 2011 but did not adequately disclose the risk to patients or, in some cases, even to the healthcare providers performing the procedure.
The SEC Disclosure Allegation
A recurring theme is that Zeltiq disclosed PAH to investors before disclosing it to patients. According to attorneys who represented Linda Evangelista, Zeltiq’s 2012 annual SEC filing warned of “possible additional liability from claims related to known rare side effects” including “paradoxical hyperplasia,” while the CoolSculpting consumer homepage carried no general safety warning until February 2019.2Newsweek. Linda Evangelista Shares Lawsuit Details After Cosmetic Procedure Allergan Aesthetics has said PAH was included in provider-facing materials and patient information starting in 2012, after the first reported case in late 2011.3Allergan Aesthetics. CoolSculpting FAQ
Some individual complaints go further. In one New Jersey case, the plaintiff alleged she was never presented with any paperwork, never signed an informed consent form, and was never warned the procedure could result in permanent deformities.4GovInfo. Fenton v. Velocity Wellness Institute et al.
Design Defect
Design defect claims have faced a steep evidentiary hurdle. Courts have required plaintiffs to identify a specific defect or a feasible alternative design, not just to point to a known side effect. In one Northern District of California case, defendants argued the plaintiff “failed to cite any actual, concrete solutions” or identify a specific product defect.5Law Street Media. AbbVie, Allergan and Others Move to Dismiss Personal Injury Suit Over Fat Reduction Device
How Cases Have Gone So Far
Linda Evangelista’s Settlement
The best-known case was filed in September 2021 in New York by former supermodel Linda Evangelista against Zeltiq Aesthetics.6Los Angeles Times. Linda Evangelista CoolSculpting Case7USA Today. Linda Evangelista Settles CoolSculpting Lawsuit8CNN. Linda Evangelista Cosmetic Lawsuit Settled The suit sought $50 million. It settled in July 2022 for an undisclosed amount, with Evangelista saying she was “pleased to have settled” and “happy to put this matter behind me.”
Cates v. Zeltiq and the Learned Intermediary Doctrine
The most important appellate ruling so far went to the manufacturer. On July 21, 2023, the Eleventh Circuit affirmed summary judgment for Zeltiq in Cates v. Zeltiq Aesthetics, Inc. Applying Florida’s learned intermediary doctrine, which holds that a medical device manufacturer’s duty is to warn the healthcare provider rather than the patient directly, the court found Zeltiq’s warnings “legally adequate as a matter of law.” The user manual and training materials described PAH as a rare adverse event, warned it could require surgical intervention, and noted it was unlikely to resolve on its own.9U.S. Court of Appeals for the Eleventh Circuit. Cates v. Zeltiq Aesthetics, Inc.
The nurse practitioner who treated Cates believed PAH was caused by patients failing to follow post-treatment instructions, not by the device. The court held that a provider’s subjective misunderstanding does not make a manufacturer’s warnings inadequate. The design defect claim also failed under both the consumer expectations test and the risk-utility test because no evidence of a feasible alternative design was presented.9U.S. Court of Appeals for the Eleventh Circuit. Cates v. Zeltiq Aesthetics, Inc.
Chubchai v. AbbVie
Plaintiffs have tried to reach past Zeltiq to hold parent AbbVie directly liable, arguing that corporate mergers made the two essentially one entity. In Chubchai v. AbbVie (Case No. 4:21-cv-4099), Judge Yvonne Gonzalez Rogers dismissed the claims against AbbVie in April 2022 for lack of personal jurisdiction, finding that Zeltiq remained an active, independently capitalized company and that overlapping officers or shared office space were not enough to pierce corporate separation.10FindLaw. Chubchai v. AbbVie Inc PLC A later-filed case under the same plaintiff name (4:22-cv-06309) was dismissed with prejudice by stipulation before the court ruled on a pending motion to dismiss.11CourtListener. Chubchai v. AbbVie, Inc. Docket
Fenton v. Velocity Wellness
In a New Jersey case, AbbVie removed the suit to federal court and argued the local medical providers were “fraudulently joined” to defeat federal jurisdiction. In July 2024, U.S. District Judge Robert Kirsch rejected that argument, finding AbbVie failed to show it was legally impossible for the plaintiff to state a valid claim against the local defendants, and remanded the case to New Jersey state court.4GovInfo. Fenton v. Velocity Wellness Institute et al.
Recalls Plaintiffs Point To
The FDA has issued Class 2 recalls for CoolSculpting components that plaintiffs have cited in litigation. In July 2021, recall Z-2383-2021 covered 1,105 CoolSculpting Elite systems over a faulty error messaging system that could fail to alert users during a thermal event, raising the risk of freeze burns; that recall was terminated in November 2023.12FDA. CoolSculpting Elite Recall Z-2383-2021 In 2022, Zeltiq initiated a voluntary recall and discontinuation of several older parallel plate applicators (CoolCore, CoolCurve, CoolCurve+, CoolMax, and CoolFit) after an internal data analysis of the 2019–2021 period identified an increased rate of PAH tied to those models. That recall (Z-1348-2022) covered 703 units.13FDA. CoolSculpting System Recall Z-1348-2022 A parallel Health Canada recall was issued in June 2022 for the same applicators.14Health Canada. CoolSculpting System Applicator Vacuum Recall The FDA has not changed its overall clearance of the CoolSculpting system and has not issued a standalone safety communication specifically about PAH.15Cleveland Clinic. CoolSculpting Side Effects
How Often PAH Actually Happens
How often PAH occurs is contested, and the answer matters to both liability and damages. Allergan Aesthetics has maintained a rate of roughly 1 in 3,000 treatments (about 0.033%),3Allergan Aesthetics. CoolSculpting FAQ and its current consumer-facing safety disclosures place the rate between 0.01% and 0.1% of procedures.16PR Newswire. Allergan Aesthetics Announces Fourth Annual All-Access CoolMonth Earlier estimates were even lower, around 1 in 20,000 based on a 2014 report in the Journal of the American Medical Association.15Cleveland Clinic. CoolSculpting Side Effects
Independent research has found higher rates. A multicenter retrospective study of more than 8,600 treatment cycles across eight Canadian centers reported PAH rates between 0.05% and 0.39% per cycle depending on the device model, two to fifteen times the manufacturer’s original figure.17Wiley Online Library. Paradoxical Adipose Hyperplasia Literature Review Older applicator models were associated with dramatically higher PAH rates than newer ones.18National Center for Biotechnology Information. Paradoxical Adipose Hyperplasia After Cryolipolysis The manufacturer’s figure is also reported per treatment cycle, not per patient; a patient who undergoes ten cycles carries a substantially higher per-patient risk than the per-cycle number suggests.
Reporting appears to have accelerated. In 2022 the FDA received over 1,900 adverse event reports related to CoolSculpting, most involving PAH, and after publicity around the Evangelista case, more than 1,100 reports were filed in a single year, more than in the entire previous decade.15Cleveland Clinic. CoolSculpting Side Effects A March 2025 MAUDE entry describes a patient who developed PAH after a 2023 treatment.19FDA MAUDE Database. MAUDE Adverse Event Report 21699653
The Current State of the Litigation
There is no class action and no consolidated multidistrict litigation for CoolSculpting injuries. Cases are being handled one by one, which means the strength of an individual claim depends heavily on the facts of that patient’s treatment: which applicator was used, what consent forms were signed, what the provider told the patient, and what state’s law applies. The Cates ruling shows that where the manufacturer’s warnings reached the provider, a failure-to-warn claim can fail even when the patient’s injury is real. The Evangelista settlement shows that individual cases can still resolve for meaningful sums when the facts are strong.
The product itself remains on the market. CoolSculpting devices are still FDA-cleared and actively promoted, and the company’s published safety information now acknowledges the risk of visible enlargement in the treated area at a rate of 0.01% to 0.1%.16PR Newswire. Allergan Aesthetics Announces Fourth Annual All-Access CoolMonth Anyone considering a claim should preserve treatment records, applicator identifiers if available, consent forms, and any photographs documenting the injury, and speak with a product liability attorney familiar with the learned intermediary doctrine in their state.